Interviews

Steven Sims, MD, discussed his upcoming research into how transnasal esophagoscopy could help address disparities in esophageal cancer diagnoses.

Troy Trygstad, PharmD, PhD, MBA, executive director of CPESN USA, discussed how consumers' expectations are changing the future of pharmacy.

Stuart Staggs, senior director of strategic programs at McKesson, discussed the encouraging metrics associated with use of the Oncology Care Model (OCM) sponsored by the Centers for Medicare and Medicaid Services.

Ned Milenkovich, PharmD, JD, licensed pharmacist and principal at Much Law, PC, discusses the announcement of the Mark Cuban Cost Plus Drug Company, which will, in some cases, offer expensive medication at a drastically lower price without insurance.

Stacy Miller, PharmD, BCPP, the senior content management consultant at Wolters Kluwer Health, discusses clinician search data focused on mental health treatment trends and needs.

Pharmacists are essential team members for the education of patients with diabetes, especially around injection technique for patients using injectable medications, such as insulin.

Ashley Woodyard, a PharmD candidate at the Touro University California College of Pharmacy in Vallejo and co-author of an article in the January 2022 issue of Pharmacy Times®, discussed the article and the benefits of pharmacy technicians as vaccine administrators.

Anna Legreid Dopp, PharmD, the Senior Director of Clinical Guidelines & Quality Improvement at ASHP, and Bayli Larson, PharmD, the Strategic Initiatives Associate at ASHP, discuss the grant the ASHP received from the American Rescue Plan.

Ron Lanton III, Esq, principal at Lanton Law, said entrepreneur Mark Cuban's new venture into the pharmacy field is very interesting, although it maybe just another player in the mail-order pharmacy market.

Carol Routledge, PhD, chief medical and scientific officer at Small Pharma, discusses DMT, how it differs from other psychedelic medicines, and what the future holds for DMT-assisted treatments.

Data from a couple of new molecules could be encouraging for the treatment of acute myeloid leukemia and diffuse large B-cell lymphoma

In addition to data showing the durable efficacy of acalabrutinib, other data presented at ASH 2021 demonstrate that the new tablet formulation of the drug supports ease of use for patients

Most adverse effects are very tolerable and easily managed, including headaches, diarrhea, and some neutropenias or infections

Matthew Davids, MD, MMSc, associate professor of medicine at Harvard Medical School, discusses the results of a longer-term follow up for iFCR therapy for individuals with chronic lymphocytic leukemia .

Acalabrutinib could offer a high level of confidence for patients looking at a long course of disease.

Matthew Davids, MD, MMSc, associate professor of medicine at Harvard Medical School, discusses how common chronic lymphocytic leukemia is for younger individuals

Matthew Davids, MD, MMSc, associate professor of medicine at Harvard Medical School, discusses how the results of a longer term study differ for individuals who were younger with chronic lymphocytic leukemia as opposed to those who are older.

Matthew Davids, MD, MMSc, associate professor of medicine at Harvard Medical School, discusses what the results of the initial iFCR study showed and what the highlights of the longer-term follow up were for individuals with chronic lymphocytic leukemia.

Matthew Davids, MD, MMSc, associate professor of medicine at Harvard Medical School, discusses how iFCR therapy increases the chance of functional cure for younger individuals with chronic lymphocytic leukemia.

Lindsey Roeker, MD at assistant attending L1, Memorial Sloan Kettering Cancer Center, discusses her ASH 2021 presentation and addresses how the study design could affect future studies.

Lindsey Roeker, MD at assistant attending L1, Memorial Sloan Kettering Cancer Center, discusses her ASH 2021 presentation and addresses the study design and the sample demographics.

Lindsey Roeker, MD, assistant attending L1 at Memorial Sloan Kettering Cancer Center, discusses her ASH 2021 presentation and addresses the highlights of the study and how the add-on approach affect the treatment of CLL.

Lindsey Roeker, MD, assistant attending L1 at Memorial Sloan Kettering Cancer Center, discusses her ASH 2021 presentation and addresses how the addition of umbralisib and ublituximab affect those being treated with ibrutinib.

Lindsey Roeker, MD, assistant attending L1 at Memorial Sloan Kettering Cancer Center, discusses her ASH 2021 presentation and addresses some of the challenges and risk of ibrutinib as treatment for CLL.

Debra Goff, PharmD, FIDSA, FCCP, infectious diseases specialist at the Ohio State University Wexner Medical Center, discusses Clostridioides difficile awareness and potential future treatments.

Minority researchers and investigators from underrepresented communities often have access to less clinical research funding than other clinical researchers.

Nicole Ross, MSN, CRNP, AOCNP, nurse practitioner for the department of hematology/oncology​ at Fox Chase Cancer Center, discusses the challenges of treating neuroendocrine tumors in large cancer centers.

Nicole Ross, MSN, CRNP, AOCNP, nurse practitioner for the department of hematology/oncology​ at Fox Chase Cancer Center, discusses how large cancer centers are able to manage adverse events for individuals with neuroendocrine tumors.